BTAI BioXcel Therapeutics

BioXcel Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast

BioXcel Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast

NEW HAVEN, Conn., Nov. 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Thursday, November 12, 2020 at 8:30 AM Eastern Time to discuss its third quarter 2020 operating and financial results.

Conference Call & Webcast Details

Date/Time: Thursday, November 12, 2020, 8:30 AM Eastern Time

Domestic: 877-407-2985

International: 201-378-4915

The webcast will be accessible* under "Events" on the News & Media page of the Company's website at .

Replay

Domestic: 877-660-6853

International: 201-612-7415

Conference ID: 13712147

*Replay available through at least November 26, 2020

BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit .

Contact Information:

BioXcel Therapeutics, Inc.

Investor Relations:

John Graziano



1.646.378.2942

Media:

Julia Deutsch



1.646.378.2967

EN
05/11/2020

Underlying

BTAIBioXcel Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioXcel Therapeutics

 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Li...

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the market value of listed securities (“MVLS”) requirement under Nasdaq Listing Rule 5550(b)(2) (the “...

September 18, 2025 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Dat...

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p

September 10, 2025 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Glo...

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference NEW HAVEN, Conn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference to be held September 8 - 10, 2025. Date: Monday, September 8, 2025Time: 4:30 p.m. Eastern TimeWebcast Link: The live an...

September 4, 2025 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phas...

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI® BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary objective of the SERENITY At-Home trial, the preliminary results demonstrate continued effects and consistent benefit with repeat dosing across the course of the trial ...

August 27, 2025 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety...

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI® BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary objective of the SERENITY At-Home trial, the preliminary results demonstrate continued effects and consistent benefit with repeat dosing across the course of the trial Fol...

August 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch